Human erythropoietin gene delivery using an arginine-grafted bioreducible polymer system

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1360-1366

  Lee, Youngsook ^a   Nam, Hye Yeong ^a   Kim, Jaesung ^a   Lee, Minhyung ^a,b   Yockman, James W ^a   Shin, Sug Kyun ^c   Kim, Sung Wan ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Hanyang University   (South Korea)

^c Ilsan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ERYTHROPOIETIN; MESSENGER RNA; PLASMID DNA; POLYDISULFIDE AMINE; POLYMER; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG TISSUE LEVEL; DRUG UPTAKE; ERYTHROPOIESIS; HEART; HEMATOCRIT; HUMAN; HUMAN CELL; KIDNEY; LIVER; LUNG; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; RAT; RETICULOCYTOSIS; SPLEEN;

EID: 84863455207     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.62     Document Type: Article

References (51)

1. KDOQI and NKF (2002). K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1): S1-S266.
2. KDOQI and NKF (2006). KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 (5 Suppl 3): S11-S145.
3. Eschbach, JW and Adamson, JW (1985). Anemia of end-stage renal disease (ESRD). Kidney Int 28: 1-5. (Pubitemid 15023016)
4. Locatelli, F, Pisoni, RL, Combe, C, Bommer, J, Andreucci, VE, Piera, L et al. (2004). Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121-132. (Pubitemid 38072623)
5. Eschbach, JW, Egrie, JC, Downing, MR, Browne, JK and Adamson, JW (1987). Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78. (Pubitemid 17052741)
6. Rizzo, JD, Brouwers, M, Hurley, P, Seidenfeld, J, Arcasoy, MO, Spivak, JL et al.; American Society of Clinical Oncology; American Society of Hematology. (2010). American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28: 4996-5010.
7. Walsh, G (2010). Biopharmaceutical benchmarks 2010. Nat Biotechnol 28: 917-924.
8. Levin, NW, Fishbane, S, Cañedo, FV, Zeig, S, Nassar, GM, Moran, JE et al.; MAXIMA study investigators. (2007). Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 370: 1415-1421. (Pubitemid 47576167)
9. Elliott, S, Pham, E and Macdougall, IC (2008). Erythropoietins: a common mechanism of action. Exp Hematol 36: 1573-1584.
10. Gershon, D (1990). Human gene therapy. First experiment approved. Nature 346: 402. (Pubitemid 20251055)
11. Park, TG, Jeong, JH and Kim, SW (2006). Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 58: 467-486. (Pubitemid 43949425)
12. Petros, RA and DeSimone, JM (2010). Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9: 615-627.
13. Papapetrou, EP, Zoumbos, NC and Athanassiadou, A (2005). Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects. Gene Ther 12 Suppl 1: S118-S130. (Pubitemid 41541761)
14. Duncan, R (2003). The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347-360. (Pubitemid 37361705)
15. Allen, TM and Cullis, PR (2004). Drug delivery systems: entering the mainstream. Science 303: 1818-1822. (Pubitemid 38374867)
16. Miller, HI (2000). Gene therapy on trial. Science 287: 591-592.
17. Wadman, M (2000). NIH under fire over gene-therapy trials. Nature 403: 237.
18. Mastrobattista, E, van der Aa, MA, Hennink, WE and Crommelin, DJ (2006). Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 5: 115-121.
19. Heitz, F, Morris, MC and Divita, G (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157: 195-206.
20. Kim, TI, Ou, M, Lee, M and Kim, SW (2009). Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials 30: 658-664.
21. Zhao, M and Weissleder, R (2004). Intracellular cargo delivery using tat peptide and derivatives. Med Res Rev 24: 1-12. (Pubitemid 38018593)
22. Brooks, H, Lebleu, B and Vivès, E (2005). Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 57: 559-577. (Pubitemid 40255561)
23. Tung, CH and Weissleder, R (2003). Arginine containing peptides as delivery vectors. Adv Drug Deliv Rev 55: 281-294. (Pubitemid 36135919)
24. Nam, HY, Lee, Y, Lee, M, Shin, SK, Kim, TI, Kim, SW et al. (2012). Erythropoietin gene delivery using an arginine-grafted bioreducible polymer system. J Control Release 157: 437-444.
25. Koury, ST, Bondurant, MC and Koury, MJ (1988). Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71: 524-527. (Pubitemid 18089550)
26. Krantz, SB (1991). Erythropoietin. Blood 77: 419-434.
27. Dessypris, E, Graber, SE, Krantz, SB and Stone, WJ (1988). Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 72: 2060-2062. (Pubitemid 19030901)
28. Lechardeur, D, Sohn, KJ, Haardt, M, Joshi, PB, Monck, M, Graham, RW et al. (1999). Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther 6: 482-497. (Pubitemid 29192657)
29. Brines, M (2010). The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 29: 86-92.
30. Brines, M and Cerami, A (2008). Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 264: 405-432.
31. Weidemann, A and Johnson, RS (2009). Nonrenal regulation of EPO synthesis. Kidney Int 75: 682-688.
32. Goldberg, MA, Gaut, CC and Bunn, HF (1991). Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood 77: 271-277.
33. Jacobson, LO, Goldwasser, E, Fried, W and Plzak, L (1957). Role of the kidney in erythropoiesis. Nature 179: 633-634.
34. Zanjani, ED, Poster, J, Burlington, H, Mann, LI and Wasserman, LR (1977). Liver as the primary site of erythropoietin formation in the fetus. J Lab Clin Med 89: 640-644. (Pubitemid 8082916)
35. Dame, C, Fahnenstich, H, Freitag, P, Hofmann, D, Abdul-Nour, T, Bartmann, P et al. (1998). Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 92: 3218-3225. (Pubitemid 28492329)
36. Wolff, JA, Malone, RW, Williams, P, Chong, W, Acsadi, G, Jani, A et al. (1990). Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1): 1465-1468.
37. Felgner, PL and Rhodes, G (1991). Gene therapeutics. Nature 349: 351-352.
38. Lammers, T, Kiessling, F, Hennink, WE and Storm, G (2010). Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 7: 1899-1912.
39. He, CX, Tabata, Y and Gao, JQ (2010). Non-viral gene delivery carrier and its threedimensional transfection system. Int J Pharm 386: 232-242.
40. Nakase, I, Takeuchi, T, Tanaka, G and Futaki, S (2008). Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Deliv Rev 60: 598-607. (Pubitemid 351215576)
41. Stockmann, C and Fandrey, J (2006). Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol 33: 968-979. (Pubitemid 44429878)
42. Tan, CC, Eckardt, KU and Ratcliffe, PJ (1991). Organ distribution of erythropoietin messenger RNA in normal and uremic rats. Kidney Int 40: 69-76.
43. Chikuma, M, Masuda, S, Kobayashi, T, Nagao, M and Sasaki, R (2000). Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab 279: E1242-E1248.
44. Koury, ST, Bondurant, MC, Koury, MJ and Semenza, GL (1991). Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77: 2497-2503.
45. Nijhof, W, Goris, H, Dontje, B, Dresz, J and Loeffler, M (1993). Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment. Exp Hematol 21: 496-501. (Pubitemid 24212341)
46. Digicaylioglu, M and Lipton, SA (2001). Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412: 641-647. (Pubitemid 32772276)
47. Kiel, MJ and Morrison, SJ (2008). Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 8: 290-301. (Pubitemid 351432804)
48. Hojman, P, Gissel, H and Gehl, J (2007). Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther 14: 950-959. (Pubitemid 46865506)
49. Murua, A, Orive, G, Hernández, RM and Pedraz, JL (2011). Emerging technologies in the delivery of erythropoietin for therapeutics. Med Res Rev 31: 284-309.
50. Sebestyén, MG, Hegge, JO, Noble, MA, Lewis, DL, Herweijer, H and Wolff, JA (2007). Progress toward a nonviral gene therapy protocol for the treatment of anemia. Hum Gene Ther 18: 269-285. (Pubitemid 46626465)
51. Palani, S and Sarkar, CA (2008). Positive receptor feedback during lineage commitment can generate ultrasensitivity to ligand and confer robustness to a bistable switch. Biophys J 95: 1575-1589.